文献速递银屑病与炎症性皮肤病

银屑病患者使用TNF-α抑制剂与甲氨蝶呤的心血管事件风险比较

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
PubMed 文献 · J Am Acad Dermatol · 2016-10-26

本研究基于Truven MarketScan数据库,比较使用TNF-α抑制剂(TNFi)或甲氨蝶呤的成人银屑病患者的主要心血管事件风险。结果显示,12个月内TNFi使用者心血管事件发生率低于甲氨蝶呤使用者(1.45% vs 4.09%,P<.01),TNFi使用与较低的心血管事件风险相关(HR=0.55,P<.01),且累积暴露每6个月与风险降低11%相关(P=.02)。

要点

  • TNFi使用者12个月心血管事件率1.45%,低于甲氨蝶呤的4.09%。
  • TNFi总体心血管事件风险比为0.55(P<.01)。
  • TNFi累积暴露每6个月与心血管事件风险降低11%相关。

核心结论

  • 接受TNFi治疗的银屑病患者主要心血管事件风险低于接受甲氨蝶呤治疗者。
  • TNFi累积暴露与主要心血管事件风险降低相关。

研究设计与样本

  • 基于Truven MarketScan数据库(2000年第一季度至2011年第三季度)的回顾性队列研究。
  • 纳入至少2次TNFi或甲氨蝶呤处方的成人银屑病患者,分为TNFi组(N=9148)和甲氨蝶呤组(N=8581)。
  • 采用多变量Cox比例风险模型分析心血管事件风险及TNFi累积效应。

主要发现

  • 12个月时,TNFi组心血管事件 Kaplan-Meier 发生率为1.45%,甲氨蝶呤组为4.09%(P<.01)。
  • TNFi组总体心血管事件风险低于甲氨蝶呤组(HR=0.55;P<.01)。
  • 中位随访24个月期间,TNFi累积暴露每6个月与心血管事件风险降低11%相关(P=.02)。

临床怎么用

  • 对于银屑病患者,选择TNFi治疗可能有助于降低主要心血管事件风险。
  • 长期使用TNFi可能带来累积的心血管保护效应。

局限性

  • 缺乏临床评估指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is associated with increased risk for cardiovascular disease. OBJECTIVE: To compare major cardiovascular event risk in psoriasis patients receiving methotrexate or tumor necrosis factor-α inhibitor (TNFi) and to assess TNFi treatment duration impact on major cardiovascular event risk. METHODS: Adult psoriasis patients with ≥2 TNFi or methotrexate prescriptions in the Truven MarketScan Databases (Q1 2000-Q3 2011) were classified as TNFi or methotrexate users. The index date for each of these drugs was the TNFi initiation date or a randomly selected methotrexate dispensing date, respectively. Cardiovascular event risks and cumulative TNFi effect were analyzed by using multivariate Cox proportional-hazards models. RESULTS: By 12 months, TNFi users (N = 9148) had fewer cardiovascular events than methotrexate users (N = 8581) (Kaplan-Meier rates: 1.45% vs 4.09%: P < .01). TNFi users had overall lower cardiovascular event hazards than methotrexate users (hazard ratio = 0.55; P < .01). Over 24 months' median follow-up, every 6 months of cumulative exposure to TNFis were associated with an 11% cardiovascular event risk reduction (P = .02). LIMITATIONS: Lack of clinical assessment measures. CONCLUSIONS: Psoriasis patients receiving TNFis had a lower major cardiovascular event risk compared to those receiving methotrexate. Cumulative exposure to TNFis was associated with a reduced risk for major cardiovascular events.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wu JJ, Guérin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2016. PMID: 27894789. doi:10.1016/j.jaad.2016.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。